Allison Bratzel

Stock Analyst at Piper Sandler

(1.95)
# 1291
Out of 5,386 analysts
40
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:
17 Stocks
Name Action PT Current % Upside Ratings Updated
REPL Replimune Group
Maintains: Overweight
14 22
9.31 136.31% 2 Jun 2, 2025
TYRA Tyra Biosciences
Assumes: Overweight
33
9.16 260.26% 1 May 21, 2025
RARE Ultragenyx Pharmaceu...
Maintains: Overweight
140 115
36.51 214.98% 1 Mar 17, 2025
AKBA Akebia Therapeutics
Maintains: Overweight
4 6
3.65 64.38% 1 Mar 14, 2025
INZY Inozyme Pharma
Maintains: Overweight
30 23
4 475% 1 Mar 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
26
3.66 610.38% 1 Feb 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
620 725
559.65 29.55% 13 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
12 22
14.76 49.05% 2 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
15 23
19.51 17.89% 2 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
65 62
39.83 55.66% 1 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
28 42
35.76 17.45% 3 Oct 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 22
11.41 92.81% 2 Jul 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
4 4
2.12 88.68% 2 Mar 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
8 20
4.73 322.83% 4 Mar 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Overweight
20
3.6 455.56% 1 Oct 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
23 25
n/a n/a 1 Apr 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
100
68.36 46.28% 2 Feb 8, 2023